linjc16/ctgov huggingface dataset:
Neurotomy of Optic Nerve in Non-Arthritic Anterior Ischemic Optic Neuropathy

Study Overview
=================
Brief Summary
-----------------
Non-arthritic anterior ischemic optic neuropathy is the most common cause of sudden visual loss due to optic nerve involvement in patients above 50 years old. As this problem can be considered as a sclera out let syndrome an there is no effective and successful treatment for it, we decided to do a neurotomy procedure and relax the involved optic nerve in order to achieve acceptable treating outcome.

Conditions
-----------------
Non Arthritic Anterior Ischemic Optic Neuropathy

Intervention / Treatment
-----------------
* Procedure: optic nerve neurotomy


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients with non-arthritic anterior ischemic optic nerve Exclusion Criteria: Visual acuity more than 20/200 Other intra occular operations Passing more than 4 weeks of the problem Arthritic anterior ischemic optic nerve Age under 50 years Consumption of previous pharmaceutical treatment

Ages Eligible for Study
-----------------
Minimum Age: 50 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Intervention/Treatment |
| --- |
|Procedure: optic nerve neurotomy|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
non arthritic ischemic optic neuropathy, anterior ischemic optic neuropathy, Optic nerve Neurotomy
The Erlangen Fitness and Prevention Study (EFOPS).

Study Overview
=================
Brief Summary
-----------------
The study determines the long-term effect of exercise on osteoporotic fracture risk. Since actually no controlled supervised exercise study exceeds the time frame of 4 years, knowledge concerning the long-term effect of exercise on fractures and fracture-risk factors is scarce. Within the Erlanger Fitness and Osteoporosis Study (EFOPS, an ongoing controlled exercise study with currently 16 years of supervised exercise with 45-50 osteopenic, early-postmenopausal women in exercise and sedentary control group each, the investigators therefore focus on overall-fractures, Bone Mineral Density and falls.

Official Title
-----------------
Effects of Exercise on Fracture Risk, Bone Mineral Density and Falls in Postmenopausal Women. The Long-term Erlangen Fitness and Prevention Study.

Conditions
-----------------
Osteoporosis, Osteopenia, Early Postmenopause

Intervention / Treatment
-----------------
* Procedure: physical exercise


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: participants of the EFOPS-study, 12 years of exercise training according to the EFOPS-protocol (exercise). Exclusion Criteria: medication and diseases affecting bone metabolism, inflammable diseases, cardiovascular diseases, start of relevant physical exercise programs beside the EFOPS protocol.

Ages Eligible for Study
-----------------
Minimum Age: 48 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: exercise<br>endurance,balance, power, resistance type exercise | Procedure: physical exercise<br>* Two sessions/week, 50 weeks/year over 12 years of high intensity exercise training<br>|
| No Intervention: sedentary control<br>Subjects were instructed to do not relevantly change their lifestyle | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| overall-fractures (low-trauma) | As assessed by questionnaire and structured interview | 16 year follow-up | 
| Bone Mineral Density at Lumbar Spine and Proximal Femur | As assessed by Dual-Energy X-ray Absorptiometry (DEXA) | 16 year follow-up | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| 10-year coronary heart disease (CHD) risk | As assessed by Framingham Risk Factor Calculator according to Wilson. | 16 year follow-up | 
| Metabolic Syndrome Z-Score | Metabolic Syndrome Z-Score Index according to Johnson | 16 year follow-up | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Osteoporosis, exercise, fractures, Bone Mineral Density, CHD-risk
Celiac Disease Database

Study Overview
=================
Brief Summary
-----------------
The focus of this study is to create a database containing information about patients with celiac disease. This database will allow us to examine clinical and epidemiologic features of the University of Chicago Medical Center patient population. We have the largest population of patients with celiac disease in the mid-West and as such this study using information gathered from our database can greatly contribute to our current understanding of this disease.

Detailed Description
-----------------
This database will allow us to examine clinical and epidemiologic features of the University of Chicago Medical Center patient population.

Official Title
-----------------
University of Chicago Celiac Disease Database

Conditions
-----------------
Celiac Disease

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Must be a patient at The University of Chicago Medical Center Clinical diagnosis of celiac disease or gluten sensitivity Exclusion Criteria: Currently being treated at a healthcare facility other than The University of Chicago Medical Center Not diagnosed with celiac disease or gluten sensitivity

Ages Eligible for Study
-----------------
Minimum Age: 0 Years
Maximum Age: 70 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Celiac Disease
Pyrotinib Combined With Trastuzumab And Chemotherapy in HER2-positive MBC

Study Overview
=================
Brief Summary
-----------------
To explore the real world data of trastuzumab Combined With Trastuzumab And Chemotherapy in China, and to explore the relationship between progression free survival and treatment pattern.

Official Title
-----------------
Pyrotinib Combined With Trastuzumab and Chemotherapy in HER2-positive Metastatic Breast Cancer Patients- a Multicenter Retrospective Study

Conditions
-----------------
HER2-positive Breast Cancer, Metastatic Breast Cancer

Intervention / Treatment
-----------------
* Drug: Trastuzumab


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: woman, age > 18 years old Diagnosed with HER2 +Metastatic Breast Cancer Pyrotinib Combined With Trastuzumab And Chemotherapy for at least one cycle, starting from 2020.11.01-2021.10.31 Available medical history Exclusion Criteria: Incomplete medical history

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 70 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Pyrotinib and Trastuzumab group<br>Dual anti-HER2 therapy (pyrotinib and trastuzumab) and chemotherapy | Drug: Trastuzumab<br>* Dual anti-HER2 therapy<br>* Other names: Pyrotinib;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Progression free survival(PFS) | The time from starting pyrotinib until disease progression or death from any cause. | 1 year | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Overall survival(OS) | The time from starting pyrotinib until death, regardless of cause. | 1 year | 
| Objective Response Rate(ORR) | The proportion of patients with complete response (CR) or partial response (PR) | 1 year | 
| Safety | Number of participants with adverse events which were collected at 6 and 18 months after the start of pyrotinib | 1 year |
P16 Staining as Prognostic Biomarker in Serous Papillary Endometrial Cancer

Study Overview
=================
Brief Summary
-----------------
P16 is a tumor suppressor protein implicated in serous papillary endometrial carcinoma. Evidence from previous trials indicates that it may be used as a diagnostic biomarker distinguishing this disease from endometrioid endometrial cancer. Additional evidence points to its prognostic value. The current study will evaluate p16 both as a diagnostic tool for serous papillary endometrial cancer and as a prognostic biomarker. following anonymization, histology blocks will be microtomed and stained for P16 and P53 proteins. Blocks from endometrioid endometrial cancer will be used as a control group.

Official Title
-----------------
Expression of the P16 Protein in Serous Papillary Endometrial Cancer, and Its Clinical and Prognostic Significance

Conditions
-----------------
Serous Papillary Endometrial Cancer

Intervention / Treatment
-----------------
* Other: no intervention


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: diagnosis of endometrial cancer histology block exists in hospital's library Exclusion Criteria: none

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Serous papillary endometrial ca patients<br>30 patients diagnosed with SP endometrial ca | Other: no intervention<br> <br> |
| Endometrioid endometrial ca<br>32 patients diagnosed with Endometrioid endometrial ca | Other: no intervention<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Overall survival |  | last followup (2-10 years) | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| progression free survival |  | Current follow up (2-10 years) | 
| correlation of P16 stain with histological diagnosis |  | at last follow up (2-10 years) | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Serous Papillary Endometrial Cancer, Endometrioid endometrial cancer, biomarkers, P16, P53, Prognosis
Hypofractionated Radiotherapy for Lung Cancer

Study Overview
=================
Brief Summary
-----------------
The purpose of this trial is to pilot reducing the duration of radiation treatment for lung cancer patients from 6 to 5 weeks using tomotherapy. Specific patient doses will be based on tumor volume being treated. Modeling has shown that increased biologically effective dose (BED) to tumors can be achieved by shortening the radiation delivery schedule and increasing the dose per fraction. This requires decreasing the total dose to hold lung toxicity constant at each dose per fraction level. This is a major paradigm shift in the treatment in this disease and is projected to result in significant improvements in patient outcome as well as a substantial cost savings.

Official Title
-----------------
The Use of Helical Tomotherapy to Achieve Dose-per-fraction Escalation in Lung Cancer

Conditions
-----------------
Lung Cancer

Intervention / Treatment
-----------------
* Radiation: radiation therapy (radiotherapy)


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Thoracic neoplasm requiring at lest 60 Gy conventional radiotherapy Exclusion Criteria: Prior bleomycin or gemcitabine chemotherapy Prior thoracic radiotherapy

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Bin 1<br>bin assignment based on tumor volume | Radiation: radiation therapy (radiotherapy)<br>* Bin assignment based on tumor volume<br>|
| Experimental: Bin 2<br>Bin assignment based on tumor volume | Radiation: radiation therapy (radiotherapy)<br>* Bin assignment based on tumor volume<br>|
| Experimental: Bin 3<br>Bin assignment based on tumor volume | Radiation: radiation therapy (radiotherapy)<br>* Bin assignment based on tumor volume<br>|
| Experimental: Bin 4<br>Bin assignment based on tumor volume | Radiation: radiation therapy (radiotherapy)<br>* Bin assignment based on tumor volume<br>|
| Experimental: Bin 5<br>Bin assignment based on tumor volume | Radiation: radiation therapy (radiotherapy)<br>* Bin assignment based on tumor volume<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Grade 3 pneumonitis lasting greater than 2 weeks |  | 90 days post radiotherapy (XRT) |
The Prevalence of Malocclusion Development in a Group of Egyptian Children With Digit Sucking Aged 3 to 6 Years

Study Overview
=================
Brief Summary
-----------------
The purpose of the study is to determine the prevalence of malocclusion among a group of Egyptian children with digit sucking aged 3 to 6 years.

Detailed Description
-----------------
The purpose of the study is to determine the prevalence of malocclusion among a group of Egyptian children with digit sucking aged 3 to 6 years. PICO: Population: Egyptian Children with digit sucking aged 3 to 6 years. Outcome: Development of malocclusion.

Official Title
-----------------
The Prevalence of Malocclusion Development in a Group of Egyptian Children With Digit Sucking Aged 3 to 6 Years: A Cross Sectional Study

Conditions
-----------------
Children With Digit Sucking

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Children between ages 3 to 6 years. Children those are medically free. Both genders are included. Egyptian children Exclusion Criteria: History of an obvious alternative cause for malocclusion (e.g. trauma, syndromes). Participants exposed to thumb sucking prevention programs. Participants who underwent orthodontic treatment for his/her malocclusion. Participants' caregivers refuse to give consent.

Ages Eligible for Study
-----------------
Minimum Age: 3 Years
Maximum Age: 6 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Anterior open bite | Measured using a divider and the measurement is transferred onto a ruler. measuring unit is mm. | 6 months | 
| Over bite. | measured using a periodontal probe and the measurement is transferred onto a ruler. measuring unit mm. | 6 months | 
| Over jet. | measured using a periodontal probe and the measurement is transferred onto a ruler. measuring unit mm. | 6 months | 
| Anterior and posterior cross bite. | Observed visually.Binary units: (yes/no) | 6 months |
Sequence Towards Remission in Depression

Study Overview
=================
Brief Summary
-----------------
In this study the investigators use clinical, biological and imaging markers to develop predictive markers for remission from depression. The investigators compare individuals who have received placebo to individuals who have received 10 mg of escitalopram for one week. In this double-blind, randomized study the investigators a) compare the groups to observe the short-term effects of escitalopram and b) study the predictive value of these observations with respect to remission. Measures include, but are not restricted to, limbic emotional reactivity as assessed by fMRI, emotional processing, emotional memory, autobiographical memory.

Official Title
-----------------
Sequence Towards Remission in Depression

Conditions
-----------------
Depression

Intervention / Treatment
-----------------
* Drug: escitalopram 10 mg
* Drug: Placebo


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Major depressive disorder with current major depressive episode according to a SCID-I/P interview Montgomery-Åsberg depression rating score 15-30 Age 18-60 Exclusion Criteria: Borderline, schizoid or schizotypal personality, bipolar or any psychotic disorder Primary diagnosis is anxiety disorder: 300.00, .01, .02, .21, .22, .29, .23, .3, 309.81, 308.3, 293.89 Significant current suicidal ideation, or history of a suicide attempt Lifetime substance dependence; Last-year substance abuse; Last month over 24/16 standard doses of alcohol/week; Lifetime use of illicit substances > x5; Any illicit substance use in last month Depressive disorder due to medical condition or chemical substance Antidepressant medication use in last 4 months Severe, unstable somatic illness Use of antipsychotics, mood stabilizers, systemic corticosteroids, β-blockers or daytime benzodiazepines (a small dose of ≤10mg zolpidem once daily is permissible)

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 60 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Placebo Comparator: Placebo<br>Microgranular cellulose in gelatine capsules. | Drug: Placebo<br>* once daily<br>|
| Experimental: Escitalopram 10 mg<br>Escitalopram in gelatine capsule | Drug: escitalopram 10 mg<br>* orally once daily<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Montgomery-Åsberg rating scale |  | 7 weeks | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Depression, emotional processing, fMRI, autobiographic memory, moderator of treatment response, mediator of treatment response
Significance of Immunohistochemical Expression of Survivin in Renal Cell Carcinoma

Study Overview
=================
Brief Summary
-----------------
detection of Survivin expression in renal cell carcinoma and correlate this expression to tumor grade and stage.

Detailed Description
-----------------
renal cell carcinoma is the third most prevalent malignant tumor of the genitourinary system. deregulation of apoptosis is involved in carcinogenesis by abnormally prolonged cell survival, facilitating accumulations of multiple mutations and augment resistance to immune-surveillance. Survivin is a member of inhibitor of Apoptosis Protein family (IAPs). it play a role in cell cycle regulation by inhibiting apiptosis. Survivin is over-expressed in many human neoplasms.

Official Title
-----------------
A Retrospective Study

Conditions
-----------------
Renal Cell Carcinoma

Intervention / Treatment
-----------------
* Diagnostic Test: sectioning and staining of renal neoplasms after nephrectomy operation


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: patients suffer from renal cell carcinomas Exclusion Criteria: patients received pre-operative chemotherapy or radiotherapy. patients with insufficient clinical data.

Ages Eligible for Study
-----------------
Minimum Age: 30 Years
Maximum Age: 70 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Diagnostic Test: sectioning and staining of renal neoplasms after nephrectomy operation|nephrectomy operations will be done to patients diagnosed as having renel tumors|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| expression of survivin in neoplastic and adjacent normal renal tissues | Survivin is highly expressed in neoplastic renal tissues compared to normal ones by immunohistochemical measures.. | april, 2021 | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Survivin, Renal Cell Carcinoma, Immnuohistochemistry
Hip Fracture Characterization With Ultrasound Exam

Study Overview
=================
Brief Summary
-----------------
Hip fractures are usually classified according to their X-ray as subcapital, pertrochanteric. We examine hip fractures with ultrasound in order to characterize the fractures with several parameters.

Conditions
-----------------
Hip Fractures

Intervention / Treatment
-----------------
* Procedure: ultrasound examination of the hip


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: patients over 50 years with x rays showing a hip fracture Exclusion Criteria: previous fracture or surgical intervention in the hip fracture over 3 days old pregnancy flexion contracture of hip

Ages Eligible for Study
-----------------
Minimum Age: 50 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Procedure: ultrasound examination of the hip|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
hip, fracture, ultrasound